September 16, 2022<\/p>\n
Amsterdam, the Netherlands \u2013<\/strong>\u00a0Royal Philips<\/u><\/a>\u00a0(NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest innovations and cardiology solutions designed to strengthen clinical confidence, build efficiency throughout the care pathway and improve cardiac care experiences at the\u00a0Transcatheter Cardiovascular Therapeutics<\/u><\/a>\u00a0(TCT) annual meeting (Boston, USA, September 16-19). In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.<\/p>\n \u201cAt Philips, we are fully focused on supporting physicians to improve the health and well-being of the patients they serve. Some of the most ground-breaking work we are doing to achieve this is happening in cardiology,\u201d said Chris Landon, General Manager, Image Guided Therapy Devices at Philips. \u201cTCT attendees will have the opportunity to see first-hand our complete set of solutions designed to provide clinicians with the diagnostic and therapeutic devices they need to optimize the workflow and improve outcomes for each individual patient.\u201d<\/p>\n An interactive cardiology experience with Philips at TCT 2022<\/strong> Philips\u2019 latest technology advancements in diagnostic, interventional and monitoring solutions at TCT 2022 include:<\/p>\n Published clinical data presented at TCT 2022<\/strong> New study validates ambulatory monitoring as a valuable, cost-neutral tool<\/strong> A recent study, \u201cCosts and Outcomes of Mobile Cardiac Outpatient Telemetry Monitoring Post-Transcatheter Aortic Valve Replacement<\/u><\/a>,\u201d published in the August issue of the\u00a0Journal of Comparative Effectiveness Research<\/em>, examined the impact that using\u00a0Philips MCOT<\/u><\/a>\u00a0(Mobile Cardiac Outpatient Telemetry) had on patient outcomes and value of high-quality care following TAVR procedures. The study revealed that MCOT-monitored TAVR hospital patients were more than 16% more likely to receive a permanent pacemaker through a scheduled physician referral than unmonitored patients (100% MCOT vs 83.5% non-MCOT), helping to avoid unplanned readmissions [6]. The study illustrates that prescribing MCOT to patients post-TAVR may provide an opportunity for improved health outcomes or cost savings by monitoring for arrhythmic disturbances, and, if detected, allowing for timely intervention via pacemaker and the avoidance of costly and dangerous emergency care.<\/p>\n For the full calendar of events, as well as general information about Philips\u2019 presence at the show, visit\u00a0www.philips.com\/TCT<\/u><\/a>. Visit the Philips Engagement Hub to experience innovative cardiac solutions and follow the #TCT2022 conversation on\u00a0@PhilipsLiveFrom<\/u><\/a>\u00a0throughout the event.<\/p>\n Refer to full Philips Laser System device labeling and instructions for important safety information. Caution: Federal law restricts this device to sale by or on the order of a physician.<\/p>\n [1] Lawton J. et al. 2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization.\u00a0JACC.<\/em>\u00a02022;79(2):e21-e129. For further information, please contact:<\/strong><\/p>\n Joost Maltha Fabienne van der Feer About Royal Philips<\/strong><\/p>\n Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being and enabling better outcomes across the health continuum \u2013 from healthy living and prevention, to diagnosis, treatment, and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at\u00a0www.philips.com\/newscenter<\/u><\/a>.<\/p>\n Attachments<\/strong><\/p>\n September 16, 2022 Global consensus data recommends the use of intravascular ultrasound (IVUS) in many peripheral vascular disease (PVD) procedures Philips Engagement Hub at TCT to feature a range of\u00a0physician-led discussions, in-depth symposia, and hands-on trainings that address some of today\u2019s most pressing cardiology challenges Amsterdam, the Netherlands \u2013\u00a0Royal Philips\u00a0(NYSE: PHG, AEX: PHIA), a global [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"yoast_head":"\n
\nVisitors to TCT 2022 will have access to Philips\u2019 latest solutions, plus opportunities to engage with clinical experts and experience innovative cardiac solutions. Philips will be hosting hands on demonstrations, symposia and discussions on topics that range from how to start an ultra-low contrast PCI program, to amplifying gender equality in medicine. Visitors will also have the opportunity to learn more about\u00a0Philips Azurion<\/u><\/a>, the next generation image-guided therapy platform,\u00a0Philips Interventional Applications Platform \u2013 IntraSight<\/u><\/a>, which optimizes lab performance with its imaging, physiology and co-registration tools, and the\u00a0Philips iFR<\/u><\/a>\u00a0(Instant Wave-free Ratio) with its evidence-based methodology that improves outcomes, saves time, and reduces patient discomfort. Philips iFR is the only resting index to earn a Class IA guideline recommendation from the ACC\/AHA\/SCAI and ESC based on clinical evidence of its accuracy [1, 2].<\/p>\n\n
\nIVUS consensus and large-scale, real-world data summary:\u00a0<\/strong>On Saturday, September 17, at 11:30am ET in the Philips Engagement Hub,\u00a0 Eric A. Secemsky, MD, Interventional Cardiologist at Beth Israel Deaconess Medical Center and Assistant Professor of Medicine at Harvard Medical School in Boston, MA, will review two critically important data sets released in late 2021 that highlight the importance of IVUS for both arterial and venous procedures, including the new consensus document from 30 global vascular experts, which recommends routine use of IVUS as a preferred imaging modality in all phases in many peripheral vascular disease (PVD) procedures, published in the August 2022 issue of the\u00a0Journal of the American College of Cardiology: Cardiovascular Interventions<\/em>\u00a0as \u201cAppropriate Use of Intravascular Ultrasound During Arterial and Venous Lower Extremity Interventions<\/u><\/a>.\u201d<\/p>\n
\nMany patients with severe symptomatic aortic stenosis (SAS) are treated with a transcatheter aortic valve replacement (TAVR) \u2013 a minimally invasive procedure that replaces a diseased aortic valve with a prosthetic valve. As an alternative to open-heart aortic valve replacement surgery, TAVR treatment offers several benefits for symptomatic SAS patients, including reduced length of hospital stay and an increased likelihood of home discharge [5].<\/p>\n
\n[2] 2018 ESC\/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS).\u00a0Eur Heart J<\/em>. 2018;00:1-96.
\n[3]\u00a0\u00a0Philips Laser System Data Sheet Specifications.<\/u><\/a>
\n[4] Dippel et al. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-stent Restenosis: Initial ISR Results (2015). JACC 8(1): 92-101.
\n[5] Arora S, Strassle PD, Kolte D, et al. Length of stay and discharge disposition after transcatheter 283 versus surgical aortic valve replacement in the United States. Circ Cardiovasc Interv. 2018;11(9). 284 doi:10.1161\/circinterventions.
\n[6] Belinda A Mohr, PhD1, et al. Impact of Mobile Cardiac Outpatient Telemetry Post-Transcatheter Aortic Valve Replacement on Costs and Outcomes: A Medicare Claims Analysis. J. Comp. Eff. Res. 2022.\u00a0\u00a0https:\/\/www.futuremedicine.
\nPhilips Global Press Office
\nTel.: +31 610 558116
\nE-mail:\u00a0joost.maltha@philips.com<\/u><\/a><\/p>\n
\nPhilips Image Guided Therapy
\nTel: + 31 622 698 001
\nE-mail:\u00a0fabienne.van.der.feer@philips.\n